ADAC_UoN NIHR Nottingham BRC NIHR Nottingham BRC Imaging Uni of Nottingham Press Office ‘Core Outcome Measures in Effectiveness Trials (COMET) Initiative’ at University of Liverpool, which has provided a public database of outcomes for clinical trials making it easier for researchers to find which outcomes are recommended as measures @COMETInitiative (original COMET members📷🔽)

Here is ChatGPT auto-writing a letter of medical necessity for liquid biopsy for a patient with metastatic breast cancer. References and all!

One word: RANDOMIZE 👇🏻👇🏻

My first publication at ⁦CEVR⁩ leveraging SPEC data. Coverage of #Makena unlikely to change until FDA withdraws the drug; leaving the drug on the market furthers health plan inaction. ⁦⁦Peter Neumann⁩ ⁦James Chambers⁩ healthaffairs.org/do/10.1377/for…

This panel on streamlining FDA and CMS processes was a great way to wrap up #isporannual. Panelists touched on accelerated approval, CED, lessons learned from #alzheimers mabs, and more. Peter Neumann Sean Tunis Anna Kaltenboeck

Made it to the interactive Withings FR exhibit in Paris today! Props to the team for a great event showing off what these technologies can do and the difference they can make in people’s lives. So glad we could make it!

Capacity-enhancing innovations enable access to innovative care while reducing burdens on healthcare providers and hospitals ➡ Recognizing this value, measuring, and rewarding it, requires adaptive HTA methods to inform policy makers’ decisions. We are sponsoring the “Value

Let us introduce you to the expert panel at the “Value Creation And Efficiency Gains Through #CapacityEnhancing #Innovations To Address Workforce Shortage” symposium. 🎤 Mr. Seth Clancy 🎤 Ms. @Tanyamareehall 🎤 Pr. Danny Liew 🎤 Dr. Wija Wija Oortwijn 🎤 Dr. Laura Laura Sampietro-Colom

Déjà vu? Here's an excerpt from FDA CBER Director's decision memo on his rationale for accelerated approval of Sarepta's Elevidys, where he discusses why he overrode his own medical reviewers who did not find clear efficacy evidence for 4-5 year olds. fda.gov/media/169707/d…

In Health Affairs Forefront today, Sean Tunis & I explore key questions for #Medicare’s real-world data collection strategy for new #Alzheimers therapies. tinyurl.com/h2aw6jrc CEVR #RWE Alzheimer's Drug Discovery Foundation Alzheimer's Association ISPOR HTAi Alzforum 1/2

- When will data collection infrastructure be ready? - How will data on benefits/risks be collected? - How will data be entered & by whom? - What impact on patient access? - How much will this cost & who pays? - Will it show opportunities for a “learning health care system”? 2/2

In their new Forefront article, Sean Tunis + Peter Neumann of CEVR discuss the FDA's upcoming decision regarding approval for Leqembi (lecanemab), a monoclonal antibody for patients with mild cognitive impairment or mild Alzheimer’s disease. bit.ly/448tzUz

Doctors are worried that #AI and robotic technology will replace them. Can #HTA protect the doctor-patient relationship? @dollendorf Barry Liden Sean Tunis #HTAi2023Adelaide

“#HTA is most robust around things that can be parameterized and measured. You can measure things like workforce satisfaction, utilization of staff, etc. HTA will be most helpful at broadening the range of parameters to measure technologies that are #CapacityEnhancing.” Adds

What do CMSGov's latest statements on coverage of #Alzheimers therapies mean for future evidence generation and patient access? Sean Tunis and I unpack the issues Health Affairs. tinyurl.com/h2aw6jrc #rwe CEVR

Hey all - I am going over the Thread and will be deleting my twitter account. Hope to find many of you again over there.

The new CMSGov registry for #Alzheimer's drugs is a start, but seems unlikely to answer key clinical outcomes questions any time soon -- even with links to #Medicare claims data. (Subscription required) tinyurl.com/ympkpzek Sean Tunis CEVR #Leqembi

My new NEJM Perspective with Sean Tunis: CMSGov is becoming a major #HTA organization. It should embrace the role. tinyurl.com/3f56499a CEVR Tufts Medical Center Arnold Ventures HTAi UW School of Pharmacy @SchaefferCenter Stacie Dusetzina #heor Anna Kaltenboeck Joey Mattingly

Attending #ISPOR2024? Check out our panel on FDA advisory committees - this Sun, 5/5, 5:30-6:30, Rm A411, Congress Center - Joseph Daval, JD, Program On Regulation, Therapeutics, And Law - Sean Tunis, MD, Rubix Health - me USC Price School @SchaefferCenter Moderator: David Howard (David Howard) Emory Public Health